NCT05177068 2025-10-02
Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer
Henan Cancer Hospital
Phase 2 Active not recruiting
Clinical Trials
35 trialsNCT07194005 2025-09-26
Remission
Fudan University
Phase 2 Recruiting
NCT05161572 2025-06-18
NeoRacing
Fudan University
Phase 2 Terminated
NCT07025889 2025-06-18
IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer
Ruijin Hospital
Phase 1/2 Recruiting
NCT07018063 2025-06-12
YOUNG-NEOS
Peking University People's Hospital
Phase 2 Not yet recruiting
NCT06977061 2025-05-16
Efficacy and Safety of Fruquintinib Combined With Sintilimab and Stereotactic Body Radiation Therapy (SBRT) for the Second-line and Higher-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Oligometastatic Progression
Second Affiliated Hospital of Nanchang University
Phase 2/3 Not yet recruiting
NCT06925243 2025-04-22
Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Lanzhou University Second Hospital
Phase 3 Recruiting
NCT05427487 2025-02-25
Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours
ImmVirx Pty Ltd
Phase 1 Recruiting
NCT06730373 2024-12-31
First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
Qilu Hospital of Shandong University
Phase 2 Recruiting
NCT06748508 2024-12-27
FDZL-GC003
Fudan University
Phase 2 Not yet recruiting
NCT06697366 2024-11-20
Liposomal Irinotecan Combined with Sintilimab for Second-line Treatment of Progressive Gastric Cancer
Ruijin Hospital
Phase 2 Not yet recruiting
NCT05625737 2024-09-19
Fruquintinib Combined with Sintilimab As Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
NCT06564298 2024-08-28
A Study on the Combination of Sintilimab, Ramucirumab and Chemotherapy for First-line Treatment of Gastric Cancer With Liver Metastasis
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting
NCT06499610 2024-07-12
Clinical Study of Irinotecan Liposome Combination Therapy for Advanced Gastric Cancer
First Affiliated Hospital Xi'an Jiaotong University
Phase 4 Not yet recruiting
NCT06454435 2024-06-12
Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT06447636 2024-06-07
Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma
Fudan University
Phase 2 Not yet recruiting
NCT06383559 2024-04-25
Safety and Efficacy of XELOX Combined With Sintilimab and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT06341595 2024-04-02
Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT05918094 2024-01-26
Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
Sun Yat-sen University
Phase 3 Recruiting
NCT06227325 2024-01-26
Disitamab Vedotin Combined With Sintilimab and XELOX Perioperative Treatment for Resectable Gastric Caner With HER2 Overexpression
Henan Cancer Hospital
Phase 2 Unknown
NCT06091423 2023-11-30
XELOX Combined With Fruquintinib and Sintilimab Regimen Conversion Therapy for Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Only With Liver and/or Retroperitoneal Lymph Node Metastasis, a Prospective Single-arm, Multicenter Study
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT06094868 2023-10-23
Clinical Study of Fruquintinib Combined With Sintilimab and XELOX Regimen in the Treatment of Advanced Cancer
Second Affiliated Hospital of Nanchang University
Phase 2 Not yet recruiting
NCT06046963 2023-09-21
Sintilimab in Combination With S-1/Oxaliplatin With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT05795296 2023-08-30
Efficacy and Safety of Fruquintinib With Sintilimab as First-line Therapy in Gastric Cancer
RenJi Hospital
Phase 2 Unknown
NCT04267549 2023-07-06
Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05928897 2023-07-05
Efficacy and Safety of Disitamab Vedotin Combined With Sintilimab
Xiangya Hospital of Central South University
Phase 2 Unknown
NCT03745170 2023-03-01
Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Completed
NCT05720533 2023-02-09
Disitamab Vedotin Combined With Sintilimab as First-line Treatment of Elderly Patients With Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05627414 2022-11-25
Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05594381 2022-10-26
A Biomarker Study for Predicting the Efficacy of Neoadjuvant Sintilimab Plus SOX for Gastric Adenocarcinoma.
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT05216237 2022-04-11
A Study to Evaluate the Efficacy and Safety of Sintilimab Plus Apatinib and Chemotherapy in Patients With HER-2 Negative Microsatellite Stability (MSS) Advanced or Metastatic Gastric (GC) or Gastroesophageal Junction (GEJ) Cancer
Affiliated Hospital of Qinghai University
Phase 2 Unknown
NCT05002686 2021-08-24
Safety and Efficacy of Sintilimab in Combination With Chemoradiothrapy Followed by D2 Surgical Resection in Patients With Advanced Gastric Cancer With Retroperitoneal Lymph Node Metastasis
Ruijin Hospital
Phase 2/3 Unknown
NCT04781413 2021-03-04
Nab-PTX Plus S-1 and Sintilimab as Adjuvant Therapy in Patients With Stage IIIC Gastric Cancer
Ruijin Hospital
Phase 1/2 Unknown
NCT04567069 2020-09-28
Safety and Efficacy Study for MG-7-DC Vaccine in Gastric Cancer Treatment
The Second Hospital of Shandong University
Phase 1/2 Unknown
NCT04263870 2020-02-11
CTSCAPOXSEA
Sichuan University
Phase 2 Unknown